MD Anderson Cancer Center

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies.

Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.

Two MD Anderson Cancer Center researchers were elected to the National Academy of Medicine for contributions to cancer care and research.

MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.

MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.

ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.

The CD70-targeting CAR T cell therapy, ALLO-316, demonstrated encouraging results in previously treated patients with advanced ccRCC.

An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.

Seventy percent of patients with B-cell ALL had residual levels of cancer cells eliminated during treatment with inotuzumab ozogamicin.

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

The University of Texas MD Anderson Cancer Center announced that Albert Koong, MD, PhD, has been appointed chief scientific officer.

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.

The FDA has issued a ‘safe to proceed’ for an application for a novel CAR T-cell therapy in CD94-positive lymphomas.

The University of Texas MD Anderson Cancer Center released recent oncology research highlights.

Jennifer Wargo, MD, of The University of Texas MD Anderson Cancer Center, has been elected to the 2026 class of Fellows of the American Association for Cancer Research (AACR) Academy.

Theresa Guise, MD, and Stephanie S. Watowich, PhD, of The University of Texas MD Anderson Cancer Center, have been elected fellows of the American Association for the Advancement of Science.

Peter WT Pisters, MD, received the Charles M. Balch, MD, Distinguished Service Award at the 2026 Society of Surgical Oncology Annual Meeting 

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center appointed new members to advance the institute’s immunotherapy work.

At The University of Texas MD Anderson Cancer Center, research breakthroughs are made through collaboration between leading clinicians and scientists.

MD Anderson data scientist Iakovos Toumazis, PhD, will further IDSO's goal to bring data science to inform decision-making for cancer control and public health.

Cancer vaccine, NOUS-209 was found to stimulate the immune system and target precancerous cells in Lynch Syndrome according to MD Anderson Cancer center.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.